E7: The Outlook for Pharmaceuticals to 2012 is a new collection of management reports from Espicom Business Intelligence. Each report provides an individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually or as a discounted collection. 7 Markets Covered!
Brazil, India, Mexico, Turkey,
China, Indonesia and Russia. Highlights from the report: BRAZIL
Due to the depreciation of the US dollar, the Brazilian pharmaceutical market is experiencing high growth in dollar values. The Brazilian pharmacy sector was valued at US$9.8 billion in 2006, ahead of the pharmacy sector in Mexico, valued at US$9.6 billion. Drug prices continue to increase in spite of generic competition. The generics sector is dominated by local producers, restricting the market entry for foreign producers. In 2006, generics sales amounted to US$1.1 billion, equal to 10.7% of the overall pharmacy sector. Generics sales will continue to outperform the pharmacy sector, fuelled by generics production of oral contraceptives & hormones and blockbusters losing their patents.

CHINA
The Chinese pharmaceutical market has shown impressive growth in recent years, in tandem with the country's rapid economic expansion. The influx of foreign multinationals in recent years has offered continued investment, and production plants and R&D facilities are being expanded all the time. Improvements in regulatory practices are making the ability to sell imported products quicker and easier, while the lowering of tariffs on imported goods and an increase in transparency of legislation has made a notoriously hard-to-penetrate market a more attractive proposition for overseas companies. The market is heavily reliant on locally-produced generics or copy products. Intellectual property provision is theoretically strong; China became a WTO member in 2001. However, enforcement remains a major issue, with courts tending to favour local producers.

INDIA
With a population of over one billion and a significant middle class capable of paying for advanced medicines, the pharmaceutical market in India has enormous potential and Espicom projects sustainable market growth of around 8.4% per year, putting the market at US$15.6 billion by 2012. It should be noted, however, that if calls for an end to drug price controls come to fruition, short-term market growth is likely to be much higher. Even allowing for liberalisation, prices are unlikely to soar with the advent of product patent recognition. The government will retain the power to intervene in cases where prices are considered high in order to protect the interests of the poorer sections of society. Also, the market will remain dominated by generics for the foreseeable future and fierce price competition in this sector will remain. The gradual introduction of new, proprietary medicines is unlikely to have a significant effect on the overall value of the market.

INDONESIA
The Indonesian pharmaceutical market has developed well in recent years, imports have begun to show a steady positive trend, rising by over one quarter in 2004. Domestic manufacturing continues to grow and the possibilities of mergers between some of the nation's leading companies should serve to boost the sector. Some leading firms are beginning to undertake their own R&D, although this is in its infancy. As the economy seeks to recover from the recession of 1998, Indonesia has become an inexpensive place to produce goods destined for export. It is hoped that investment from abroad may increase thus strengthening the industry, and prospects for the market appear good in the short-term. Espicom estimates a healthy growth rate of around 7.0%, and expects the Indonesian market to surpass the US$2 billion mark for the first time by 2010.

MEXICO
The Mexican pharmaceutical market is the other leading Latin American market, and the tenth largest worldwide. International and domestic producers compete in the Mexican market, and continue to increase exports towards Europe and the USA. Geographically, Mexico can serve the needs of well established pharmaceutical markets such as the USA and Canada, and also the emerging Latin American pharmaceutical markets. For a long time, drug counterfeiting has been a major problem in Mexico. Around 10% of the pharmacy sector is counterfeit, equal to around US$740 million in 2003, with a high incidence in Guadalajara and Monterrey. Often, well-known organisations have to go public to defend the quality of their drug supplies, the latest being the Social Insurance Institute of State Employees (ISSSTE) in November 2006.

RUSSIA
In 2007, the Russian pharmaceutical market is estimated at US$7.8 billion, equal to around US$44 per capita. The market is split between imported products and cheap locally produced generics. Imports account for around 74% of the pharmaceutical market. The Russian pharmaceutical market is predicted to expand at an average rate of 15.9% over the next few years, due to the new public pharmaceutical reimbursement system and the growing demand for expensive drugs.

TURKEY
Espicom estimates the Turkish pharmaceutical market to be worth US$6 billion in 2007, equal to US$80 per capita. The market is expected to grow by 6.9% annually, to reach US$8.3 billion or US$105 per capita by 2012. This progress however, could be further hampered by the uncertain political and economic climate prevailing in Turkey. Growth will be mainly due to a continued reliance on pharmaceutical imports, an ageing population and a growing demand for ever more complex treatment options.
FOR EVERY MARKET

MARKET OUTLOOK
Current market size
Unique 5-Year market projections to 2012
Market outlook
Comment & rating, covering 8 key areas such as use of generic drugs, intellectual property, pricing and the health systems
Market structure
Statistical data on imports and exports
Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, funding and
government policy
Key national data projections

FOR EVERY MARKET

BACKGROUND DATA
Population data, including growth trends and age structure
Demographic indicators detailing principal causes of death and morbidity

HEALTHCARE SYSTEM
Organisation & administration
Health expenditure
- Expenditure by source of funding and type
Hospital services
- Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures
Outpatient care
Medical personnel
- Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists

ACCESSING THE PHARMA MARKET
Regulatory environment
Distribution guide and trade fair information
Domestic production

CONTACT DETAILS
Healthcare organisations
Trade associations